CTOs on the Move

Zynerba

www.zynerba.com

 
Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zynerba.com
  • 80 West Lancaster Avenue Suite 300
    Devon, PA USA 19333
  • Phone: 484.581.7505

Executives

Name Title Contact Details

Similar Companies

DxTech

DxTech LLC is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sionna Therapeutics

We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis.

10X Genomics

10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms short-read sequencing technologies. Our Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.

Forge Biologics

Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups.

Mavupharma

Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.